<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Sancilio Pharmaceuticals Company, Inc. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=29871></link><description><![CDATA[Sancilio Pharmaceuticals Company, Inc. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Wed, 29 Apr 2026 16:05:47 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2017/11/3698601005_20171102164035_1225759713.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Altemia™ Achieves Successful Clinical Results in Pediatric Patients with Sickle Cell Disease (SCD)]]></title><link>https://www.newswire.co.kr/newsRead.php?no=859026</link><description><![CDATA[RIVIERA BEACH, Fla.--(Business Wire/Korea Newswire)--Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced positive top line results from a clinical study evaluating the efficacy and safety of AltemiaTM, an oral soft gelatin dosage form, in pediatric sickle cell patients aged 5-17 years .  Sickle cell disease is characterized by an imbalance of certain fatty acids in blood cell membranes r...]]></description><pubDate>Thu, 02 Nov 2017 16:45:00 +0900</pubDate></item><item><title><![CDATA[Altemia™, 겸형 적혈구 빈혈증(SCD) 소아 환자에 대한 성공적인 임상 결과 달성]]></title><link>https://www.newswire.co.kr/newsRead.php?no=859028</link><description><![CDATA[리비에라 비치, 플로리다--(Business Wire/뉴스와이어)--산실리오 파마슈티컬스 컴퍼니(Sancilio Pharmaceuticals Company, Inc., 이하 SPCI)가 5~17세 소아 겸형 적혈구 빈혈증(Sickle Cell Disease, SCD) 환자들을 대상으로 경구용 연질 젤라틴 투여제 알테미아(AltemiaTM)의 효능과 안전성을 평가하는 3상 임상시험 결과를 1일 발표했다.  겸형 적혈구 빈혈증은 혈액 세포막 내의 특정 단백질 아미노산의 불균형으로 특징지어지...]]></description><pubDate>Thu, 02 Nov 2017 16:45:00 +0900</pubDate></item></channel></rss>